Ascendiant Capital Markets Comments on RenovoRx Q1 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for RenovoRx in a note issued to investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will post earnings per share of ($0.06) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $13.50 price objective on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS and Q4 2027 earnings at ($0.05) EPS.

RenovoRx (NASDAQ:RNXT) last issued its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). RenovoRx had a negative return on equity of 119.77% and a negative net margin of 994.48%.The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.42 million. During the same quarter last year, the business earned ($0.40) earnings per share.

A number of other research firms have also commented on RNXT. Wall Street Zen lowered RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RenovoRx in a research report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of RenovoRx in a research report on Wednesday, April 8th. Finally, JonesTrading raised RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

RenovoRx Price Performance

NASDAQ RNXT opened at $1.02 on Tuesday. The firm has a market cap of $45.95 million, a P/E ratio of -3.19 and a beta of 1.22. The stock’s 50-day moving average is $0.95 and its 200-day moving average is $0.99. RenovoRx has a one year low of $0.70 and a one year high of $1.45.

Institutional Investors Weigh In On RenovoRx

A number of hedge funds and other institutional investors have recently bought and sold shares of RNXT. Wealthspire Advisors LLC acquired a new stake in RenovoRx in the 4th quarter valued at approximately $212,000. AIGH Capital Management LLC raised its position in RenovoRx by 8.4% in the 4th quarter. AIGH Capital Management LLC now owns 2,833,894 shares of the company’s stock valued at $2,380,000 after buying an additional 218,701 shares during the last quarter. Citadel Advisors LLC acquired a new stake in RenovoRx in the 3rd quarter valued at approximately $154,000. Northwestern Mutual Wealth Management Co. acquired a new stake in RenovoRx in the 2nd quarter valued at approximately $98,000. Finally, Bleichroeder LP raised its position in RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after buying an additional 61,379 shares during the last quarter. Institutional investors and hedge funds own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.